Collectively, this study along with the study with Nutlin-3a implicated a potential therapeutic mechanism through targeting p53-Mdm2 complex against many EBV associated B-cell lymphomas expressing functionally active p53. This evidence concerns the gene TP53 and B-cell non-Hodgkin lymphoma.